We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$406M
(-15%)
Cap. Flow
+$12.3M
Cap. Flow
% of AUM
0.52%
Top 10 Holdings %
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
25
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$32.6M |
| 2 |
Eli Lilly
LLY
|
+$25.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$22.3M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$15.3M |
| 5 |
WELL.PRI
Welltower Inc.
WELL.PRI
|
+$11.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$58.6M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$38.9M |
| 3 |
Illumina
ILMN
|
+$13.4M |
| 4 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$12.5M |
| 5 |
ALR
Alere Inc
ALR
|
+$11.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.09% |
| 2 | Miscellaneous | 6.05% |
| 3 | Real Estate | 4.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LKFT
126
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.8B
| $836K | 0.04% |
20,000
| – | – |
|
|
RVNC
127
DELISTED
Revance Therapeutics, Inc.
RVNC
| $786K | 0.03% |
+45,000
| New | +$916K |
|
|
BLCM
128
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $561K | 0.02% |
6,000
| – | – |
|
|
GNMK
129
DELISTED
GenMark Diagnostics, Inc
GNMK
| $492K | 0.02% |
93,349
| – | – |
|
130
Celldex Therapeutics
CLDX
$3.03B
| $400K | 0.02% |
7,053
| – | – |
|
131
Xencor
XNCR
$1.77B
| $268K | 0.01% |
20,000
| – | – |
|
132
The RMR Group
RMR
$328M
| $186K | 0.01% |
7,441
| – | – |
|
133
Larimar Therapeutics
LRMR
$399M
| $89K | ﹤0.01% |
1,109
| – | – |
|
134
AbbVie
ABBV
$463B
| $9K | ﹤0.01% |
156
| – | – |
|
|
GWPH
135
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-30,000
| Closed | -$2.08M |
|
|
WCG
136
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-88,652
| Closed | -$6.93M |
|
|
ALR
137
DELISTED
Alere Inc
ALR
| – | – |
-297,901
| Closed | -$11.6M |
|
|
BXLT
138
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| – | – |
-319,600
| Closed | -$12.5M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, Tekla Capital Management held 145 positions worth $2.35B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Tekla Capital Management's Q1 2016 filing shows 11 new, 25 increased, 9 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 179,091 shares worth $23.4M. The largest sale was Johnson & Johnson, an estimated $58.6M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Real Estate.
- Tekla Capital Management's largest Q1 2016 buy was Jazz Pharmaceuticals: 179,091 shares worth $23.4M.
- Tekla Capital Management added most to Medtronic in Q1 2016, an estimated $32.6M increase.
- Tekla Capital Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $58.6M.
- Tekla Capital Management fully exited BAXALTA INC COM STK (DE) in Q1 2016, selling an estimated $12.5M.
- Tekla Capital Management's ten largest holdings make up 43% of its $2.35B portfolio in Q1 2016.
- Tekla Capital Management opened 11 new positions and closed 5 in Q1 2016.
- Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.35B.
Based on Tekla Capital Management's 13F filing for Q1 2016, filed 9 May 2016.